# language_name_wals:	English
# language_name_glotto:	English
# ISO_6393:	eng
# year_composed:	NA
# year_published:	NA
# mode:	written
# genre_broad:	technical
# genre_narrow:	NA
# writing_system:	Latn
# special_characters:	NA
# short_description:	EMEA
# source:	https://object.pouta.csc.fi/OPUS-EMEA/v3/raw/en.zip
# copyright_short:	http://opus.nlpl.eu/EMEA.php
# copyright_long:	http://opus.nlpl.eu/EMEA.php J. Tiedemann, 2012, Parallel Data, Tools and Interfaces in OPUS. In Proceedings of the 8th International Conference on Language Resources and Evaluation (LREC 2012)
# sample_type:	whole
# comments:	NA

ed e nd sp
ANNEX tio
n I
Su
SUMMARY OF PRODUCT CHARACTERISTICS isa or uth gA tin ker Ma
1/ 17 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis Pesti emulsion for injection
ed 2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance:
Classical Swine Fever Virus (CSFV) -E2 subunit antigen:
120 Elisa Units (EU) per dose of 2 ml
nd Adjuvant:
941.4 mg liquid paraffin per dose of 2 ml
e For a full list of excipients, see section 6.1
sp 3.
PHARMACEUTICAL FORM
Su Emulsion for injection.
4.
CLINICAL PARTICULARS
n 4.1 Target species tio Pigs. isa
4.2 Indications for use, specifying the target species
Active immunisation of pigs from the age of 5 weeks onwards to prevent mortality and to reduce clinical signs of Classical Swine Fever, as well as to reduce infection with and excretion of CSF field virus. or
The onset of protection is 2 weeks.
The duration of protection is 6 months. uth
4.3 Contraindications
None gA
4.4 Special warnings for each target species
None tin
4.5 Special precautions for use
Special precautions for use in animals ke
Not applicable
Special precautions to be taken by the person administering the veterinary medicinal product to r
animals Ma
To the user:
This product contains mineral oil.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package
2/ 17 leaflet with you.
If pain persists for more than 12 hours after medical examination, seek medical advice again.
To the physician:
This product contains mineral oil.
Even if small amounts have been injected, accidental injection with
ed this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit.
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
nd 4.6 Adverse reactions (frequency and seriousness)
A local and in most cases transient swelling at the injection site may occur up to 4 weeks after
e administration of each dose of the vaccine.
Transient hyperthermia may occur post the second dose.
Abscesses may be observed at the injection site.
Since safety after giving both inoculations at the same
sp site has not been examined, it is advised to carry out the second vaccination at a different site than the first vaccination.
Su 4.7 Use during pregnancy, lactation or lay
Can be used during pregnancy but may not prevent transplacental transmission of Classical swine fever field virus from the sow to foetuses.
4.8 n Interaction with other medicinal product and other forms of interaction tio No information is available on the safety and efficacy from the concurrent use of this vaccine with any other.
It is therefore recommended that no other vaccines can be administered concurrently with the product. isa
4.9 Amounts to be administered and administration route
Shake well before use. or
Intramuscular injection of one dose (2 ml) in the neck in the area behind the ear.
Vaccination scheme: uth
Basic vaccination: injection.
Inject one dose per pig followed by a second injection 4 weeks after the first
Re-vaccination:
Every 6 months, using a single dose.
Allow the vaccine to reach a temperature of 15°C-25°C before use.
Use sterile syringes and needles.
Avoid the introduction of contamination. gA
Vaccinate healthy animals only.
It is recommended to use a closed multiject vaccination system.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary tin
After administration of an overdose, local reactions at the injection site may be more pronounced.
4.11 Withdrawal period(s) ke
Zero days r Ma
5.
IMMUNOLOGICAL PROPERTIES
Classical Swine Fever vaccine, ATC vet code:
QI09AD04 The active substance stimulates active immunity against Classical Swine Fever (CSF).
The product contains Classical Swine Fever virus E2 immunogen incorporated in an emulsion in order to prolong stimulation of the immune system of the target species.
As a consequence of the subunit nature of the vaccine, vaccination does not induce production of antibodies against CSF virus antigens, other than E2.
3/ 17 6.
PHARMACEUTICAL PARTICULARS
6.1 List of excipients
ed Polysorbate 80 Sorbitan oleate
6.2 Incompatibilities
nd Do not mix with any other vaccine or immunological product.
e 6.3 Shelf life
sp 3 years.
Shelf life after first broaching the bottle:
3 hours.
Su 6.4 Special precautions for storage
Store in a refrigerator (2°C to 8°C).
Do not freeze.
6.5 Nature and composition of immediate packaging
n tio Bottles of type I hydrolytic glass or polyethylene terephthalate (PET) containing 50 ml for 25 doses, 100 ml for 50 doses and 250 ml for 125 doses presentation.
The bottles are closed with a nitryl rubber stopper and sealed with a coded aluminum cap.
The bottles are packed individually in a carton box. isa
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products or
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. uth
7.
MARKETING AUTHORISATION HOLDER
Intervet International B. V. gA
Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands tin
8.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 99/ 016/ 001-006 ke
9.
DATE OF THE FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION r Ma
06/ 2005
10.
DATE OF REVISION OF THE TEXT
21/ 03/ 2006
4/ 17 Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. eu. int/
PROHIBITION OF SALE, SUPPLY AND/ OR USE
ed The import, sale, supply and/ or use of Porcilis Pesti is only allowed under the particular conditions established by European Community legislation on the control of CSF (Council Directive 80/ 217/ EEC, as amended).
Any person intending to import, sell, supply and/ or use the veterinary medicinal product
nd must be authorised by the competent authority of the Member State.
e sp Ma
r ke
tin
gA
uth
or
isa
tio
n
Su
5/ 17 ed
tio
n Su
sp
e
nd
ANNEX II
A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR isa
BATCH RELEASE
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE or
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING uth
AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
D.
STATEMENT OF THE MRLs gA tin ker Ma
6/ 17 A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Manufacturer of the biological active substance:
ed Nobilon International BV Exportstraat 39b 5830 AH Boxmeer
nd The Netherlands
or
e Intervet International B. V.
sp Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands
Su Manufacturer responsible for batch release
Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer n The Netherlands tio B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION isa
REGARDING SUPPLY OR USE
To be supplied only on veterinary prescription. or
According to Community Legislation on Classical swine fever (Council Directive 80/ 217/ EEC, as amended), in the European Union: uth
a) The use of classical swine fever vaccines is prohibited.
However, the use of vaccines may be authorised in the framework of an emergency vaccination plan, implemented by the competent authority of a Member State following confirmation of disease, in accordane with Community Legislation on control and eradication of classical swine fever; gA
b) The storage, supply, distribution and sale of classical swine fever vaccines must be carried out under the control of and in accordance with the eventual instructions established by the competent authority of the Member State; tin
c) Special provisions regulate the movement of pigs from areas where classical swine fever vaccine is being or has been used and the marking of pigmeat from vaccinated pigs. r ke Ma
7/ 17 C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
According to Article 71 of Directive 2001/ 82/ EC of the European Parliament and of the Council, Member States prohibit or/ may prohibit the import, sale, supply and/ or use of Porcilis Pesti on the
ed whole or part of their territory if it is established that:
a) the administration of the product to animals will interfere with the implementation of national programmes for the diagnosis, control and elimination of animal diseases, or will cause
nd difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals
e b) the disease to which the product is intended to confer immunity is largely absent from the territory.
sp D.
STATEMENT OF THE MRLs
Su Annex II of Council Regulation (EEC) No 2377/ 90 Pharmacologically active substance Liquid paraffin (Mineral hydrocarbons)1 Polysorbate 80 2 Sorbitan mono-oleate 3 (E494)
Animal Species All food-producing species n tio
Other provisions
isa or uth gA tin r ke Ma
1 OJ No.
L 291 of 06.12.95 2 OJ No.
L 290 of 05.12.95 3 OJ No.
L 272 of 25.10.96
8/ 17 ed
sp
e
nd
tio
n
Su
ANNEX III
LABELLING AND PACKAGE LEAFLET isa or uth gA tin ker Ma
9/ 17 Ma rke tin gA
A. uth or
10/ 17 isa LABELLING tio
n
Su sp
end
ed
PARTICULARS TO APPEAR ON THE OUTER PACKAGE
{50ml Bottle/ 100ml Bottle/ 250ml Bottle}
ed 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
nd Porcilis Pesti
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
e sp Per dose of 2 ml:
120 Elisa Units CSF-E2 antigen.
Liquid paraffin:
941.4 mg
Su 3.
PHARMACEUTICAL FORM
Emulsion for injection
4.
PACKAGE SIZE n tio 50 ml (25 doses) – 100 ml (50 doses) – 250 ml (125 doses) isa
5.
TARGET SPECIES
Pigs or uth
6.
INDICATION(S)
Vaccine against Classical Swine Fever gA
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
IM injection of 2 ml tin
8.
WITHDRAWAL PERIOD ke
Withdrawal period -Zero days r
9.
SPECIAL WARNING(S), IF NECESSARY Ma
Accidental self-injection is dangerous
11/ 17 10.
EXPIRY DATE
< EXP {month/year} > Once broached, use within 3 hours.
ed 11.
SPECIAL STORAGE CONDITIONS
nd Store in a refrigerator (2°C to 8°C).
Do not freeze.
e 12.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
sp Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements
Su 13.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only. n To be supplied only on veterinary prescription. tio 14.
THE WORDS “ KEEP OUT OF THE REACH AND SIGHT OF CHILDREN ” isa
Keep out of the reach and sight of children. or
15.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER uth
Intervet International B. V., NL – 5831 AN Boxmeer gA
16.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 99/ 016/ 001 - EU/ 2/ 99/ 016/ 006 tin
17.
MANUFACTURER’ S BATCH NUMBER
< Batch > < Lot > < BN > {number} r ke Ma
12/ 17 MINIMUM PARTICULARS TO APPEAR ON Bottle Label
{50ml/ 100ml/ 250ml}
ed 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis Pesti
nd 2.
QUANTITY OF THE ACTIVE SUBSTANCE(S)
e 120 Elisa Units CSF E2 antigen/ 2ml.
sp 3.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
Su 50 ml (25 doses) – 100 ml (50 doses) – 250 ml (125 doses)
n 4.
ROUTE(S) OF ADMINISTRATION
tio
IM injection isa
5.
WITHDRAWAL PERIOD
Withdrawal period:
Zero days or
6.
BATCH NUMBER uth
< Batch > < Lot > < BN > {number}
7.
EXPIRY DATE gA
< EXP {month/year} > Once broached, use within 3 hours. tin
8.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” ke
For animal treatment only. r Ma
13/ 17 Ma rke tin gA uth or
14/ 17 isa B.
PACKAGE LEAFLET tio
n
Su sp
end
ed
PACKAGE LEAFLET
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
ed Intervet International B. V.
Wim de Körverstraat 35 5831 AN Boxmeer
nd The Netherlands
e 2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
sp Porcilis Pesti emulsion for injection
Su 3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Per dose of 2 ml:
120 Elisa Units Classical Swine Fever Virus-E2 subunit antigen Liquid paraffin as adjuvant:
941.4 mg/ 2 ml
n tio 4.
INDICATION(S)
Active immunisation of pigs from the age of 5 weeks onwards to prevent mortality and to reduce clinical isa
signs of Classical Swine Fever, as well as to reduce infection with and excretion of CSF field virus.
The onset of protection is 2 weeks.
The duration of protection is 6 months. or
5.
CONTRAINDICATIONS uth
None
6.
ADVERSE REACTIONS gA
A local and in most cases transient swelling at the injection site may occur up to 4 weeks after administration of each dose of the vaccine.
Transient hyperthermia may occur post the second dose.
Abscesses may be observed at the injection site.
Since safety after giving both inoculations at the same tin
site has not been examined, it is advised to carry out the second vaccination at a different site than the first vaccination.
After administration of an overdose, local reactions at the injection site may be more pronounced. ke
If you notice any serious side effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon. r Ma
7.
TARGET SPECIES
Pigs
15/ 17 8.
DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION
2 ml Intramuscular use
ed Vaccination scheme:
Basic vaccination:
Inject one dose per pig followed by a second injection 4 weeks after the first injection.
Re-vaccination:
Every 6 months, using a single dose.
nd 9.
ADVICE ON CORRECT ADMINISTRATION
e Allow the vaccine to reach a temperature of 15°C-25°C and shake well before use.
sp Administer 2 ml of vaccine deep intramuscularly in the neck area behind the ear.
Use sterile syringes and needles.
It is recommended to use a closed multiject vaccination system.
Su 10.
WITHDRAWAL PERIOD
Zero days
n tio 11.
SPECIAL STORAGE PRECAUTIONS
Keep out of the reach and sight of children. isa
Store in a refrigerator (2°C to 8°C).
Do not freeze.
Shelf-life after first broaching the bottle:
3 hours.
Do not use after the expiry date which is stated on the label. or
12.
SPECIAL WARNINGS uth
To the user:
This product contains mineral oil.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
If you are accidentally injected with this gA
product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you.
If pain persists for more than 12 hours after medical examination, seek medical advice again. tin
To the physician:
This product contains mineral oil.
Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit.
Expert, PROMPT, surgical attention is required and may necessitate early incision ke
and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
Vaccinate healthy animals only. r
The product can be used during pregnancy but may not prevent transplacental transmission of Classical Ma
swine fever field virus from the sow to foetuses.
No information is available on the safety and efficacy from the concurrent use of this vaccine with any other.
It is therefore recommended that no other vaccines can be administered concurrently with the product.
Do not mix with any other vaccine or immunological product.
16/ 17 The import, sale, supply and/ or use of this veterinary medicinal product is only allowed under the particular conditions established by European Community legislation on the control of CSF (Council Directive 80/ 217/ EEC, as amended).
Any person intending to import, sell, supply and/ or use the veterinary medicinal product must be authorised by the competent authority of the Member State.
ed 13.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
nd Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
e 14.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
sp 09/ 06/ 2000
Su Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. eu. int/
15.
OTHER INFORMATION
n For animal treatment only. tio As a consequence of the subunit nature of the vaccine, vaccination does not induce production of antibodies against CSF virus antigen, other than E2. isa
50 ml/ 100 ml/ 250 ml multidose glass bottle 50 ml/ 100 ml/ 250 ml multidose PET bottle
Not all pack sizes may be marketed. or uth gA tin r ke Ma
17/ 17